IP Library Granted Patent US 7,179,903
Granted Patent B2
US 7,179,903 · App. 10/885,457 · Granted Feb 20, 2007

Liver specific transcriptional enhancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,179,903
App. No.
10/885,457
Granted
Feb 20, 2007
Kind
B2
Abstract

Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.

Claims (9)

1. A polynucleotide comprising the nucleotide sequences of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

2. The polynucleotide of claim 1 , which comprises the nucleotide sequence of SEQ ID NO: 10.

3. The polynucleotide of claim 1 , which consists of the nucleotide sequence of SEQ ID NO: 10.

4. The polynucleotide of claim 1 , further comprising a mouse transthyretin (mTTR) promoter.

5. The polynucleotide of claim 1 , further comprising an α-1-microglobulin/bikunin enhancer and a human factor VIII endogenous promoter (L-F8).

6. A transfer vector comprising an expression control sequence operably linked to a transgene, wherein the expression control sequence comprises the polynucleotide of claim 1 .

7. The transfer vector of claim 6 , wherein the expression control sequence comprises the nucleotide sequence of SEQ ID NO: 10.

8. The transfer vector of claim 6 , further comprising a mouse transthyretin (mTTR) promoter.

9. The transfer vector of claim 6 , further comprising an α-1-microglobulin/bikunin enhancer and a human factor VIII endogenous promoter (L-F8).

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2019
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 051443/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2018
From: MILTENYI BIOTEC TECHNOLOGY, INC.
To: MILTENYI BIOTEC GMBH
Reel/Frame 045035/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2014
From: GBP IP, LLC
To: MILTENYI BIOTEC TECHNOLOGY, INC
Reel/Frame 033666/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2008
From: CELL GENESYS, INC.
To: GBP IP, LLC
Reel/Frame 020666/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2006
From: MCARTHUR, JAMES G.; TALBOT, DALE JOHN; SIMMONS, ANDREW D.; MCGUINNESS, RYAN; KELLY, MICHAEL; TSUI, LISA V.; DULL, THOMAS
To: CELL GENESYS, INC.
Reel/Frame 018429/0238 →